Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 41Recruiting 22Terminated 21Active not recruiting 17Unknown 7Not yet recruiting 6Withdrawn 5

Sponsor Class

OTHER 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × tislelizumab × Clear all
NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

BeiGene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumors

NCT05791097 2023-07-24

AdvanTIG-306

Novartis

Phase 3 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05809895 2023-07-24

AdvanTIG-211

Novartis

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT05564338 2023-06-07

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

BeiGene

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡